Q-omics provides the consensus-scored RN7SKP26 profile across patient tissues and cancer cell-line models. RN7SKP26 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP26 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RN7SKP26 RNA expression shows 12,791 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where RN7SKP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP26 survival associations across molecular data types. RN7SKP26 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP26 RNA expression–survival associations across cancer types. High RN7SKP26 expression shows unfavorable associations in UVM, but favorable associations in HNSC, ESCA, LUAD, BRCA and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for RN7SKP26 RNA expression.
This table summarizes RN7SKP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP26 shows lower tumor expression in PAAD and BRCA and higher tumor expression in KIRC, ESCA, CHOL and LUAD. The KIRC box plot shows higher RN7SKP26 RNA expression in tumor versus normal tissue (log2 FC = +0.126, t-test p = .001).
This table shows molecular features associated with RN7SKP26 in patient tissues and cancer cell lines. In patient samples, RN7SKP26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
